Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a small-cap biotech filing can feel like decoding a lab notebook—especially when Tharimmune’s disclosures span pruritus trial endpoints, antibody constructs and complex licensing terms. If you have ever asked, "How do I navigate a Tharimmune annual report 10-K simplified?" or hunted for Tharimmune insider trading Form 4 transactions, you know the challenge.
Stock Titan solves it. Our AI instantly breaks down every document—so understanding Tharimmune SEC documents with AI means plain-English summaries, key financial tables and alerts the moment a Tharimmune Form 4 insider transactions real-time filing hits EDGAR. Need the latest Tharimmune quarterly earnings report 10-Q filing? We tag R&D spend, cash runway and pipeline updates, then link them to historical trends for quick Tharimmune earnings report filing analysis. Material deal signed or FDA feedback released? The platform flags it inside the next 8-K, giving you Tharimmune 8-K material events explained before the market digests the news.
Here’s what investors regularly track:
- Phase-progress timelines, dosing cohorts and safety data tucked into 10-Q footnotes
- Licensing economics and dilution risk revealed in S-3 and S-1 shelves
- Tharimmune executive stock transactions Form 4 that signal insider confidence
- Board pay details inside the Tharimmune proxy statement executive compensation
Stop wading through 200-page PDFs. Stock Titan delivers AI-powered summaries, expert context and real-time updates on every Tharimmune filing—so you can focus on whether TH104’s buccal film or those multi-specific antibodies are the next breakthrough.
Tharimmune, Inc. (THAR) filed a Form 8-K disclosing a corporate governance update. The filing includes a Certificate of Amendment to the Certificate of Incorporation, dated October 10, 2025, furnished as Exhibit 3.1.
The excerpt does not specify the substance of the amendment, and there are no financial results, transactions, or guidance changes disclosed here. The document is signed by Chief Executive Officer Sireesh Appajosyula. Without the amendment’s details, potential effects on shareholders—such as changes to share structure or corporate provisions—are not determinable from this text.
TharImmune, Inc. discloses beneficial ownership for named executives, directors and major shareholders. Chairman Vincent LoPriore holds 1,121,770 shares (18.45%). All named executive officers and directors as a group hold 1,550,334 shares (25.61%). Institutional and large holders listed include Gravitas Capital LP: 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel: 885,644 shares (14.32%), and David Clarke: 783,842 shares (12.79%). Several other holders report positions between about 5% and 8%, and certain individual directors report smaller, de minimis stakes. The table reflects ownership percentages and share counts without forward-looking commentary.
Tharimmune, Inc. preliminary proxy excerpts show ownership stakes for directors, named executive officers and major shareholders. Vincent LoPriore is listed with 1,121,770 shares (18.45%). All named executive officers and directors as a group (7 persons) hold 1,550,334 shares (25.61%). Institutional or large holders shown include Gravitas Capital LP 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel 885,644 shares (14.32%), David Clarke 783,842 shares (12.79%), SDS Capital Partners II, LLC 485,890 shares (8.00%), GSB Holdings, Inc. 418,799 shares (6.99%), and Brightforge Management, LLC 310,910 shares (5.25%). The extract appears to be a partial table of beneficial ownership and signature lines from the preliminary proxy.
Nancy Davis Rickel, a director of Tharimmune, Inc. (THAR), filed an initial Form 3 disclosing ownership of 50,000 stock options granted on 08/04/2025. The options are exercisable into common stock at an exercise price of $1.33 per share, with 25,000 shares vesting immediately and 25,000 vesting on 08/04/2026. The filing is signed by Ms. Rickel on 08/29/2025 and was filed as an individual Form 3.
Tharimmune, Inc. is offering securities that raise approximately $4,814,996 in gross proceeds, with placement agent fees of $535,000 (10% of gross proceeds). The prospectus supplement shows common stock outstanding rising from 5,691,444 shares before the offering to 6,880,332 shares after the offering, and a pro forma net tangible book value per share of $0.09 as of June 30, 2025. Net proceeds are intended for working capital and general corporate purposes. The company states it has never paid cash dividends and does not anticipate doing so. Tharimmune’s Quatramer platform is described as a proprietary tumor-targeting approach to deliver drugs to the tumor microenvironment. The filing also discloses dependence on sole-source suppliers for certain ingredients and highlights that investing involves a high degree of risk.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
